La vendita allo scoperto per Teleflex dà agli investitori un'idea del grado in cui gli investitori stanno scommettendo sul declino delle azioni di Teleflex. I dati relativi alle vendite allo scoperto vengono aggiornati ogni due settimane.

Teleflex (NYSE:TFX) Azioni, Report sulle vendite allo scoperto

Teleflex

Teleflex is a Wayne, Pennsylvania-based manufacturer of hospital supplies and medical devices primarily in the bloodstream/vascular and surgical areas. The firm reports results across seven segments: vascular access (24% of 2023 sales), interventional (17%), anesthesia (13%), surgical (14%), interventional urology (11%), original-equipment manufacturing (11%), and other (10%). Geographic exposure for the business is primarily in the US, which accounts for 60% of revenue, with international markets making up the remainder.

Teleflex Inc

<p>Mizuho  analyst Anthony Petrone   maintains Teleflex (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TFX#NYSE">TFX</a>) with a Neutral and lowers the price target from $275 to $250.</p>


News

Price Target

Analyst Ratings

Mizuho Maintains Neutral on Teleflex, Lowers Price Target to $250

<p>RBC Capital  analyst Shagun Singh   maintains Teleflex (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TFX#NYSE">TFX</a>) with a Outperform and lowers the price target from $275 to $245.</p>


RBC Capital Maintains Outperform on Teleflex, Lowers Price Target to $245

<p>Needham  analyst Mike Matson   reiterates Teleflex (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TFX#NYSE">TFX</a>) with a Hold.</p>


Reiteration

Needham Reiterates Hold on Teleflex

WIIM

Teleflex shares are trading lower after the company reported mixed Q3 financial results and cut FY24 revenue growth guidance.

Guidance

Teleflex Lowers FY24 GAAP Revenue Growth Guidance Range From 3.40% - 4.40% To 2.90% - 3.40%, Revises Adjusted EPS From Continuing Operations Guidance From  $13.80 - $14.20 To $13.90 - $14.20, Est $13.97

<p>Teleflex (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TFX#NYSE">TFX</a>) reported quarterly earnings of $3.49 per share which beat the analyst consensus estimate of $3.39 by 2.95 percent. This is a 4.12 percent decrease over earnings of $3.64 per share from the same period last year.  The company reported quarterly sales of $764.38 million which missed the analyst consensus estimate of $769.60 million by 0.68 percent.  This is a 2.41 percent increase over sales of $746.39 million the same period last year.</p>


Earnings

Earnings Beats

Earnings Misses

Teleflex Q3 2024 Adj EPS $3.49 Beats $3.39 Estimate, Sales $764.38M Miss $769.60M Estimate

<p>Teleflex (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TFX#NYSE">TFX</a>) is gearing up to announce its quarterly earnings on Thursday, 2024-10-31. Here's a quick overview of what investors should know before the release.</p>
<p>Analysts are estimating that Teleflex will report an <strong>earnings per share</strong> (EPS) of $3.39.</p>
<p>Investors in Teleflex are eagerly awaiting the company's announcement, hoping for news of surpassing estimates and positive guidance for the next quarter.</p>
<p>It's worth noting for new investors that stock prices can be heavily influenced by future projections rather than just past performance.</p>
<h3>Overview of Past Earnings</h3>
<p>The company's EPS beat by $0.09 in the last quarter, leading to a 0.5% increase in the share price on the following day.</p>
<p>Here's a look at Teleflex's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
<th><strong>Q3 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>3.33</td>
<td>3.07</td>
<td>3.26</td>
<td>3.27</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>3.42</td>
<td>3.21</td>
<td>3.38</td>
<td>3.64</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>1.0%</td>
<td>2.0%</td>
<td>0.0%</td>
<td>1.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1730322284_0.png" alt="eps graph" /></p>
<h3>Analyst Opinions on Teleflex</h3>
<p>For investors, grasping market sentiments and expectations in the industry is vital. This analysis explores the latest insights regarding Teleflex.</p>
<p>The consensus rating for Teleflex is Outperform, based on 6 analyst ratings. With an average one-year price target of $264.5, there's a potential 11.87% upside.</p>
<h3>Understanding Analyst Ratings Among Peers</h3>
<p>In this comparison, we explore the analyst ratings and average 1-year price targets of Globus Medical, Penumbra and Glaukos, three prominent industry players, offering insights into their relative performance expectations and market positioning.</p>
<ul>
<li>As per analysts' assessments, Globus Medical is favoring an Outperform trajectory, with an average 1-year price target of $80.43, suggesting a potential 65.98% downside.</li>
<li>The prevailing sentiment among analysts is an Buy trajectory for Penumbra, with an average 1-year price target of $230.67, implying a potential 2.44% downside.</li>
<li>The prevailing sentiment among analysts is an Buy trajectory for Glaukos, with an average 1-year price target of $141.86, implying a potential 40.0% downside.</li>
</ul>
<h3>Peers Comparative Analysis Summary</h3>
<p>The peer analysis summary provides a snapshot of key metrics for Globus Medical, Penumbra and Glaukos, illuminating their respective standings within the industry. These metrics offer valuable insights into their market positions and comparative performance.</p>
<p>
<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Teleflex</td>
<td>Outperform</td>
<td>0.87%</td>
<td>$416.46M</td>
<td>1.77%</td>
</tr>
<tr>
<td>Globus Medical</td>
<td>Outperform</td>
<td>115.93%</td>
<td>$369.65M</td>
<td>0.80%</td>
</tr>
<tr>
<td>Penumbra</td>
<td>Buy</td>
<td>14.49%</td>
<td>$162.83M</td>
<td>-5.09%</td>
</tr>
<tr>
<td>Glaukos</td>
<td>Buy</td>
<td>19.02%</td>
<td>$73.14M</td>
<td>-9.06%</td>
</tr>
</tbody>
</table>
</p>
<p>Key Takeaway:</p>
<p>Teleflex ranks at the top for Gross Profit and Return on Equity among its peers. It is in the middle for Revenue Growth.</p>
<h3>Discovering Teleflex: A Closer Look</h3>
<p>Teleflex is a Wayne, Pennsylvania-based manufacturer of hospital supplies and medical devices primarily in the bloodstream/vascular and surgical areas. The firm reports results across seven segments: vascular access (24% of 2023 sales), interventional (17%), anesthesia (13%), surgical (14%), interventional urology (11%), original-equipment manufacturing (11%), and other (10%). Geographic exposure for the business is primarily in the US, which accounts for 60% of revenue, with international markets making up the remainder.</p>
<h3>Teleflex's Financial Performance</h3>
<p><strong>Market Capitalization Perspectives:</strong> The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.</p>
<p><strong>Revenue Growth:</strong> Over the 3 months period, Teleflex showcased positive performance, achieving a revenue growth rate of <strong>0.87%</strong> as of 30 June, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.</p>
<p><strong>Net Margin:</strong> Teleflex's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of <strong>10.68%,</strong> the company showcases strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Teleflex's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of <strong>1.77%,</strong> the company may face hurdles in achieving optimal financial returns.</p>
<p><strong>Return on Assets (ROA):</strong> Teleflex's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of <strong>1.07%,</strong> the company showcases efficient use of assets and strong financial health.</p>
<p><strong>Debt Management:</strong> With a below-average debt-to-equity ratio of <strong>0.4</strong>, Teleflex adopts a prudent financial strategy, indicating a balanced approach to debt management.</p>
<p><a href="https://www.benzinga.com/quote/TFX/earnings"><strong>To track all earnings releases for Teleflex visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


A Look Ahead: Teleflex's Earnings Forecast

Health Care

General

Teleflex Has Enrolled The First Patient In PPRT Trial To Evaluate Barrigel Rectal Spacer, A Sculptable Hyaluronic Acid Rectal Spacer Designed To Significantly Reduce Radiation That Reaches The Rectum During Prostate Radiation Therapy

Teleflex Announced The Launch Of Two New Devices In Canada Designed To Enhance Picc Insertion Procedures And Reduce The Chance Of Complications

<p><strong>Teleflex's</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TFX#NYSE">TFX</a>) short percent of float has risen 32.29% since its last report. The company recently reported that it has <strong>754 thousand shares sold short</strong>, which is 2.54% of all regular shares that are available for trading. Based on its trading volume, <strong>it would take traders 2.25 days to cover their short positions on average.</strong></p>
<h3>Why Short Interest Matters</h3>
<p>Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.</p>
<p>Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.</p>
<p><strong>See Also:</strong> <a href="https://www.benzinga.com/short-interest"><strong>List of the most shorted stocks</strong></a></p>
<h3>Teleflex Short Interest Graph (3 Months)</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1729614612_0.png" alt="short_fig" /></p>
<p>As you can see from the chart above the percentage of shares that are sold short for Teleflex has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.</p>
<h3>Comparing Teleflex's Short Interest Against Its Peers</h3>
<p>Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.</p>
<p>According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Teleflex's peer group average for short interest as a percentage of float is 4.24%, which means the company has <strong>less</strong> short interest than most of its peers.</p>
<p>Did you know that increasing short interest can actually be <strong>bullish</strong> for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/"><strong>This post by Benzinga Money explains how you can profit from it.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and was reviewed by an editor.</em></p>


Short Sellers

Short Ideas

Trading Ideas

Peering Into Teleflex's Recent Short Interest

<ul>
<li>Barrigel rectal spacer provides high quality rectal spacing, enabling low dose to the rectum during prostate cancer radiation therapy, with an excellent toxicity and safety profile; and low incidence (0.32-1%) of rectal wall infiltration (RWI), which can be safely reversed using hyaluronidase.</li>
<li>Data demonstrate safety and efficacy of Barrigel rectal spacer in stereotactic body radiation therapy (SBRT) for patients undergoing repeat therapy.</li>
</ul>


Teleflex Announced The Presentation Of Data Supporting The Safety And Efficacy Of Barrigel Rectal Spacer, To Reduce Radiation That Reaches The Rectum During Prostate Cancer Radiation Therapy

<p>Ratings for Teleflex (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TFX#NYSE">TFX</a>) were provided by 6 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.</p>
<p>Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $264.5, along with a high estimate of $290.00 and a low estimate of $247.00. Surpassing the previous average price target of $252.83, the current average has increased by 4.62%.</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1728921650_0.png" alt="price target chart" /></p>
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
<p>The standing of Teleflex among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Richard Newitter</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Hold</td>
<td>$255.00</td>
<td>$247.00</td>
</tr>
<tr>
<td>Shagun Singh</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$275.00</td>
<td>$260.00</td>
</tr>
<tr>
<td>Shagun Singh</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$260.00</td>
<td>$260.00</td>
</tr>
<tr>
<td>Richard Newitter</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Hold</td>
<td>$247.00</td>
<td>$240.00</td>
</tr>
<tr>
<td>Shagun Singh</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$260.00</td>
<td>$235.00</td>
</tr>
<tr>
<td>George Sellers</td>
<td>Stephens &amp; Co.</td>
<td>Raises</td>
<td>Overweight</td>
<td>$290.00</td>
<td>$275.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Teleflex. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Teleflex compared to the broader market.</li>
<li><strong>Price Targets:</strong> Gaining insights, analysts provide estimates for the future value of Teleflex's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Teleflex's market position. Stay informed and make well-informed decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/TFX/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Teleflex analyst ratings.</strong></a></p>
<h2>Unveiling the Story Behind Teleflex</h2>
<p>Teleflex is a Wayne, Pennsylvania-based manufacturer of hospital supplies and medical devices primarily in the bloodstream/vascular and surgical areas. The firm reports results across seven segments: vascular access (24% of 2023 sales), interventional (17%), anesthesia (13%), surgical (14%), interventional urology (11%), original-equipment manufacturing (11%), and other (10%). Geographic exposure for the business is primarily in the US, which accounts for 60% of revenue, with international markets making up the remainder.</p>
<h3>Teleflex: A Financial Overview</h3>
<p><strong>Market Capitalization Analysis:</strong> Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.</p>
<p><strong>Revenue Growth:</strong> Over the 3 months period, Teleflex showcased positive performance, achieving a revenue growth rate of <strong>0.87%</strong> as of 30 June, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.</p>
<p><strong>Net Margin:</strong> Teleflex's net margin excels beyond industry benchmarks, reaching <strong>10.68%</strong>. This signifies efficient cost management and strong financial health.</p>
<p><strong>Return on Equity (ROE):</strong> Teleflex's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of <strong>1.77%,</strong> the company may face hurdles in generating optimal returns for shareholders.</p>
<p><strong>Return on Assets (ROA):</strong> Teleflex's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of <strong>1.07%,</strong> the company may face hurdles in achieving optimal financial returns.</p>
<p><strong>Debt Management:</strong> With a below-average debt-to-equity ratio of <strong>0.4</strong>, Teleflex adopts a prudent financial strategy, indicating a balanced approach to debt management.</p>
<h2>Understanding the Relevance of Analyst Ratings</h2>
<p>Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. </p>
<p>Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.</p>
<p>If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Where Teleflex Stands With Analysts

<p>Truist Securities  analyst Richard Newitter   maintains Teleflex (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TFX#NYSE">TFX</a>) with a Hold and raises the price target from $247 to $255.</p>


Truist Securities Maintains Hold on Teleflex, Raises Price Target to $255

<p>RBC Capital  analyst Shagun Singh   maintains Teleflex (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TFX#NYSE">TFX</a>) with a Outperform and raises the price target from $260 to $275.</p>


RBC Capital Maintains Outperform on Teleflex, Raises Price Target to $275

<p><strong>Teleflex's</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TFX#NYSE">TFX</a>) short percent of float has risen 20.75% since its last report. The company recently reported that it has <strong>568 thousand shares sold short</strong>, which is 1.92% of all regular shares that are available for trading. Based on its trading volume, <strong>it would take traders 2.14 days to cover their short positions on average.</strong></p>
<h3>Why Short Interest Matters</h3>
<p>Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.</p>
<p>Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.</p>
<p><strong>See Also:</strong> <a href="https://www.benzinga.com/short-interest"><strong>List of the most shorted stocks</strong></a></p>
<h3>Teleflex Short Interest Graph (3 Months)</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1727374512_0.png" alt="short_fig" /></p>
<p>As you can see from the chart above the percentage of shares that are sold short for Teleflex has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.</p>
<h3>Comparing Teleflex's Short Interest Against Its Peers</h3>
<p>Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.</p>
<p>According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Teleflex's peer group average for short interest as a percentage of float is 4.37%, which means the company has <strong>less</strong> short interest than most of its peers.</p>
<p>Did you know that increasing short interest can actually be <strong>bullish</strong> for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/"><strong>This post by Benzinga Money explains how you can profit from it.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and was reviewed by an editor.</em></p>


(TFX) - Analyzing Teleflex's Short Interest

<p><strong>Teleflex's</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TFX#NYSE">TFX</a>) short percent of float has fallen 43.78% since its last report. The company recently reported that it has <strong>361 thousand shares sold short</strong>, which is 1.22% of all regular shares that are available for trading. Based on its trading volume, <strong>it would take traders 1.0 days to cover their short positions on average.</strong></p>
<h3>Why Short Interest Matters</h3>
<p>Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.</p>
<p>Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.</p>
<p><strong>See Also:</strong> <a href="https://www.benzinga.com/short-interest"><strong>List of the most shorted stocks</strong></a></p>
<h3>Teleflex Short Interest Graph (3 Months)</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1724694321_0.png" alt="short_fig" /></p>
<p>As you can see from the chart above the percentage of shares that are sold short for Teleflex has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.</p>
<h3>Comparing Teleflex's Short Interest Against Its Peers</h3>
<p>Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.</p>
<p>According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Teleflex's peer group average for short interest as a percentage of float is 4.60%, which means the company has <strong>less</strong> short interest than most of its peers.</p>
<p>Did you know that increasing short interest can actually be <strong>bullish</strong> for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/"><strong>This post by Benzinga Money explains how you can profit from it.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and was reviewed by an editor.</em></p>


How Is The Market Feeling About Teleflex?

Teleflex Announces A Review Showing That The Titan SGS Stapler Offers Consistent Gastric Pouch Formation With Fewer Variations, Potentially Enhancing Clinical Outcomes And Procedural Efficiency Compared To Traditional Staplers

<p>RBC Capital  analyst Shagun Singh   reiterates Teleflex (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TFX#NYSE">TFX</a>) with a Outperform and maintains $260 price target.</p>


RBC Capital Reiterates Outperform on Teleflex, Maintains $260 Price Target

<p>Truist Securities  analyst Richard Newitter   maintains Teleflex (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TFX#NYSE">TFX</a>) with a Hold and raises the price target from $240 to $247.</p>


Truist Securities Maintains Hold on Teleflex, Raises Price Target to $247

<p>Teleflex (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TFX#NYSE">TFX</a>) underwent analysis by 5 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.</p>
<p>In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $254.0, a high estimate of $290.00, and a low estimate of $235.00. Observing a 8.64% increase, the current average has risen from the previous average price target of $233.80. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1722632409_0.png" alt="price target chart" /></p>
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
<p>An in-depth analysis of recent analyst actions unveils how financial experts perceive Teleflex. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Shagun Singh</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$260.00</td>
<td>$235.00</td>
</tr>
<tr>
<td>George Sellers</td>
<td>Stephens &amp; Co.</td>
<td>Raises</td>
<td>Overweight</td>
<td>$290.00</td>
<td>$275.00</td>
</tr>
<tr>
<td>Richard Newitter</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Hold</td>
<td>$240.00</td>
<td>$235.00</td>
</tr>
<tr>
<td>Richard Newitter</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Hold</td>
<td>$235.00</td>
<td>$219.00</td>
</tr>
<tr>
<td>Matt O'Brien</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$245.00</td>
<td>$205.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Teleflex. This offers insight into analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Teleflex compared to the broader market.</li>
<li><strong>Price Targets:</strong> Gaining insights, analysts provide estimates for the future value of Teleflex's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Teleflex's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/TFX/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Teleflex analyst ratings.</strong></a></p>
<h2>All You Need to Know About Teleflex</h2>
<p>Teleflex is a Wayne, Pennsylvania-based manufacturer of hospital supplies and medical devices primarily in the bloodstream/vascular and surgical areas. The firm reports results across seven segments: vascular access (24% of 2023 sales), interventional (17%), anesthesia (13%), surgical (14%), interventional urology (11%), original-equipment manufacturing (11%), and other (10%). Geographic exposure for the business is primarily in the US, which accounts for 60% of revenue, with international markets making up the remainder.</p>
<h3>Financial Insights: Teleflex</h3>
<p><strong>Market Capitalization:</strong> Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.</p>
<p><strong>Revenue Growth:</strong> Teleflex displayed positive results in 3 months. As of 31 March, 2024, the company achieved a solid revenue growth rate of approximately <strong>3.79%</strong>. This indicates a notable increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.</p>
<p><strong>Net Margin:</strong> Teleflex's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of <strong>2.07%,</strong> the company may face hurdles in effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Teleflex's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of <strong>0.34%,</strong> the company may encounter challenges in delivering satisfactory returns for shareholders.</p>
<p><strong>Return on Assets (ROA):</strong> Teleflex's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of <strong>0.2%,</strong> the company may face hurdles in achieving optimal financial performance.</p>
<p><strong>Debt Management:</strong> The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at <strong>0.41</strong>.</p>
<h2>What Are Analyst Ratings?</h2>
<p>Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.</p>
<p>In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Beyond The Numbers: 5 Analysts Discuss Teleflex Stock

Larry Biegelsen, an analyst from Wells Fargo, maintained the Hold rating on Teleflex (TFX – Research Report). The associated price target remains t...

Maintaining Hold on Teleflex Amid Mixed Market Opportunities and Competitive Challenges

Teleflex Q3 2024 Earnings Preview

Teleflex Non-GAAP EPS of $3.49 beats by $0.10, revenue of $764.4M misses by $3.4M

Teleflex declares $0.34 dividend

Teleflex (TFX) is down -14.1%, or -$33.05 to $202.17. Published first on TheFly – the ultimate source for real-time, market-moving breaking financi...

Teleflex falls -14.1%

Teleflex Incorporated (TFX) Q3 2024 Earnings Call Transcript

Teleflex ( ($TFX) ) has released its Q3 earnings. Here is a breakdown of the information Teleflex presented to its investors. Teleflex Incorporated...

Teleflex Announces Q3 2024 Financial Results

In a report released yesterday, Larry Biegelsen from Wells Fargo maintained a Hold rating on Teleflex (TFX – Research Report), with a price target ...

Wells Fargo Sticks to Their Hold Rating for Teleflex (TFX)

Raymond James analyst Jayson Bedford lowered the firm's price target on Teleflex (TFX) to $245 from $266 and keeps an Outperform rating on the shar...

Teleflex price target lowered to $245 from $266 at Raymond James

In a report released today, Craig Bijou from Bank of America Securities maintained a Hold rating on Teleflex (TFX – Research Report). The company's...

Teleflex (TFX) Receives a Hold from Bank of America Securities

Press Releases

Teleflex Announces Publication of a Propensity Matching Review of Retrospective Data Reporting that the Titan SGS™ Stapler Enables Consistent Gastric Pouch Formation with Fewer Variations, Providing Potentially Enhanced Clinical Outcomes and Significant Procedural Efficiency Compared with Traditional Surgical Staplers

Teleflex to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference

Teleflex™ Chooses o9's AI-Powered Platform for End-to-End Integrated Business Planning and Supply Chain Management

Teleflex's Barrigel Rectal Spacer to Be Featured in Three Presentations at the 2024 American Society for Radiation Oncology (ASTRO) Annual Meeting

Teleflex Announces Third Quarter 2024 Earnings Conference Call Information

New Data Presented at ASTRO 2024 Further Demonstrate the Safety and Efficacy of Barrigel™ Rectal Spacer, the First and Only Sculptable Hyaluronic Acid Rectal Spacer, in Patients Undergoing Radiation Therapy for Prostate Cancer(1-3)

Comments

Teleflex

Vendite allo scoperto

Teleflex (NYSE:TFX) Azioni, Report sulle vendite allo scoperto

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO